靶向治疗时代大剂量白介素-2的作用
该研究回顾性分析了2007年7月至2014年9月接受大剂量白介素-2治疗的92例转移性肾细胞癌患者,评估其生存结局。结果显示,既往是否接受靶向治疗与总生存期和无进展生存期无显著差异,且对白介素-2的应答与后续靶向治疗的疗效独立。作者认为,经仔细筛选的患者应接受大剂量白介素-2治疗以争取完全且持久的缓解,而不必担心限制靶向治疗的获益。
要点
- 既往靶向治疗与未接受靶向治疗的患者,总生存期和无进展生存期无显著差异。
- 对白介素-2完全或部分缓解者与稳定或进展者,后续靶向治疗的总生存期无显著差异。
- 作者认为,经仔细筛选的患者应接受大剂量白介素-2治疗,以争取完全且持久的缓解。
核心结论
- 患者对白介素-2的应答与接受白介素-2前后靶向治疗的应答相互独立。
- 作者认为,经仔细筛选的患者应接受大剂量白介素-2治疗,以争取完全且持久的缓解,而不必担心限制靶向治疗的获益。
研究设计与样本
- 回顾性队列研究,纳入2007年7月至2014年9月接受大剂量白介素-2治疗的转移性肾细胞癌患者。
- 共识别92例患者,其中87例有对大剂量白介素-2应答的记录。
- 疗效评估基于RECIST(实体瘤疗效评价标准)1.1版。
- 采用Kaplan-Meier法估计无进展生存期和总生存期。
主要发现
- 整个队列自开始大剂量白介素-2治疗起的中位总生存期为34.4个月。
- 既往接受靶向治疗者与未接受既往治疗者相比,中位总生存期分别为34.4个月和30.0个月(p=0.88),无显著差异。
- 既往接受靶向治疗者与未接受既往治疗者相比,中位无进展生存期分别为1.5个月和1.7个月(p=0.8),无显著差异。
- 对大剂量白介素-2完全或部分缓解者与最佳疗效为稳定或进展者相比,后续靶向治疗的中位总生存期分别为30.1个月和25.4个月(p=0.4),无显著差异。
临床怎么用
- 作者认为,经仔细筛选的患者应接受大剂量白介素-2治疗,以争取完全且持久的缓解,而不必担心限制靶向治疗的获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed survival outcomes following high dose interleukin-2 in a contemporary cohort of patients during the era of targeted agents. MATERIALS AND METHODS: We retrospectively reviewed the records of patients with metastatic renal cell carcinoma treated with high dose interleukin-2 between July 2007 and September 2014. Clinicopathological data were abstracted and patient response to therapy was based on RECIST (Response Evaluation Criteria In Solid Tumors), version 1.1 criteria. The Kaplan-Meier method was used to estimate progression-free and overall survival in the entire cohort, the response to high dose interleukin-2 in regard to previous targeted agent therapy and the response to the targeted agent in relation to the response to high dose interleukin-2. RESULTS: We identified 92 patients, of whom 87 had documentation of a response to high dose interleukin-2. Median overall survival was 34.4 months from the initiation of high dose interleukin-2 therapy in the entire cohort. Patients who received targeted therapy before high dose interleukin-2 had overall survival (median 34.4 and 30.0 months, p = 0.88) and progression-free survival (median 1.5 and 1.7 months, p = 0.8) similar to those in patients who received no prior therapy, respectively. Additionally, patients with a complete or partial response to high dose interleukin-2 had similar outcomes for subsequent targeted agents compared to patients whose best response was stable or progressive disease (median overall survival 30.1 vs 25.4 months, p = 0.4). CONCLUSIONS: Our data demonstrate that patient responses to high dose interleukin-2 and to targeted agents before and after receiving high dose interleukin-2 are independent. As such, carefully selected patients should be offered high dose interleukin-2 for the possibility of a complete and durable response without the fear of limiting the treatment benefit of targeted agents.
引用
- Gills J, Parker WP, Pate S, et al. The Role of High Dose Interleukin-2 in the Era of Targeted Therapy. J Urol. 2017. PMID: 28288839. doi:10.1016/j.juro.2017.03.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。